We are entering another stage of the COVID-19 pandemic.
A panel of advisers to the US Food and Drug Administration (FDA) voted unanimously to propose the introduction of Moderna’s COVID-19 booster vaccines to the original vaccine for citizens aged 65 and over, in addition to people at high risk of serious illness or occupational proximity to the virus, according to initial report from Reuters.
The vote for the Moderna amplifier was 19 to zero; in favor.
While the booster shot still needs official FDA approval to move forward, we could soon begin to see an increase in prevalence, despite the fact that “the data itself is not strong,” according to Patrick Moore of the University of Pittsburgh. on Reuters report.
Moderna’s COVID-19 vaccine booster has been approved
The FDA will still have to approve the Moderna booster shot, but when that happens, the US Centers for Disease Control and Prevention (CDC) will move forward with specific recommendations on who should and who should not receive the photos. The FDA’s Advisory Committee, known as the Advisory Committee on Vaccines and Related Organic Products, reached that agreement after a meeting Thursday to consider the idea of an additional dose of Moderna vaccine. Further consideration is pending on the Johnson & Johnson vaccine in Friday.
This is a novelty for the approval of the FDA’s advisory committee on Moderna’s booster launch for its COVID-19 vaccine for the elderly, so be sure to contact us for more updates.